LLY is trading at $1020.53 (+3.1%) following positive late-stage trial results for its oral obesity medication, Foundayo, which demonstrated sustained weight loss efficacy.
- Studies published in The Lancet and Nature Medicine showed that patients successfully maintained weight loss when switching from injectable treatments like Zepbound to the oral pill.
- The clinical breakthrough has propelled the stock to outpace the broader market, with the Nasdaq up 1.09%.